Group 1 - The core viewpoint of the article highlights that Baiaoshaitu-B (02315) experienced a significant intraday increase of nearly 10%, reaching a new high of 39.46 HKD, and is currently trading at 38.72 HKD with a transaction volume of 17.64 million HKD [1] - On January 9, Baiaoshaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC project through a structured assessment mechanism, aiming to accelerate the development of the BsAD2C [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaoshaitu, which will also receive an upfront payment and subsequent payments upon the exercise of the option, including milestone payments and revenue sharing [1] Group 2 - According to a recent report by Cinda Securities, Baiaoshaitu's sales of model animals and preclinical pharmacological evaluation business are developing synergistically and are currently in a high growth phase [1] - Compared to industry peers, Baiaoshaitu's business model is relatively unique, focusing on high-margin humanized mouse strains and not offering low-margin standard strains, leading to high utilization of cage resources and the capability to expand internationally [1]
百奥赛图-B盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作